We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $532M
1-Year Est. Return 171.17%
This Fund
S&P 500
This Quarter Est. Return
+19.45%
1 Year Est. Return
+171.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$532M
AUM Growth
+$53.4M
Cap. Flow
-$19.6M
Cap. Flow %
-3.69%
Top 10 Hldgs %
56.72%
Holding
51
New
10
Increased
15
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
AVLN
Avalyn Pharma
AVLN
+$48.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
PBLS
Parabilis Medicines Inc
PBLS
+$22.8M
4
GILD icon
Gilead Sciences
GILD
+$13.9M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$11.2M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$46.1M
2
ASND icon
Ascendis Pharma A/S
ASND
+$22.7M
3
TERN
Terns Pharmaceuticals
TERN
+$21.6M
4
SLNO
Soleno Therapeutics
SLNO
+$19.3M
5
BSX icon
Boston Scientific
BSX
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
26
Eledon Pharmaceuticals
ELDN
$245M
$6.68M 1.26%
1,695,071
+55,255
+3% +$201K
FDMT icon
27
4D Molecular Therapeutics
FDMT
$827M
$6.27M 1.18%
+471,254
New +$4.59M
MANE
28
Veradermics Inc
MANE
$4.12B
$5.64M 1.06%
45,856
-127,726
-74% -$12M
DYN icon
29
Dyne Therapeutics
DYN
$4.53B
$5.44M 1.02%
244,929
-38,025
-13% -$707K
GUTS icon
30
Fractyl Health
GUTS
$111M
$4.9M 0.92%
6,168,749
+676,883
+12% +$482K
IMCR icon
31
Immunocore
IMCR
$1.86B
$4.7M 0.88%
148,045
+63,693
+76% +$1.88M
DNTH icon
32
Dianthus Therapeutics
DNTH
$6.05B
$3.21M 0.6%
32,941
-527,367
-94% -$46.1M
BBOT
33
BridgeBio Oncology
BBOT
$720M
$2.43M 0.46%
+318,407
New +$2.66M
TARA icon
34
Protara Therapeutics
TARA
$233M
$1.99M 0.37%
520,148
-59,876
-10% -$285K
HYPR icon
35
Hyperfine
HYPR
$86.2M
$1.78M 0.33%
1,320,041
– –
ATAI icon
36
AtaiBeckley Inc
ATAI
$2.74B
$1.04M 0.2%
196,858
– –
MGX icon
37
Metagenomi Therapeutics
MGX
$44.2M
$630K 0.12%
528,993
– –
OM icon
38
Outset Medical
OM
$67.5M
$511K 0.1%
118,279
– –
FTH
39
Faeth Therapeutics
FTH
$1.03B
$368K 0.07%
14,718
– –
ABVX
40
Abivax
ABVX
$10B
– –
-47,193
Closed -$5.25M
ADPT icon
41
Adaptive Biotechnologies
ADPT
$3.87B
– –
-722,784
Closed -$10M
BSX icon
42
Boston Scientific
BSX
$69.3B
– –
-299,318
Closed -$18.8M
CYTK icon
43
Cytokinetics
CYTK
$10.1B
– –
-215,501
Closed -$14.2M
KALV
44
DELISTED
KalVista Pharmaceuticals
KALV
– –
-426,551
Closed -$8.59M
NAMS icon
45
NewAmsterdam Pharma
NAMS
$3.04B
– –
-83,554
Closed -$2.67M
PHAT icon
46
Phathom Pharmaceuticals
PHAT
$769M
– –
-247,767
Closed -$2.75M
QURE icon
47
uniQure
QURE
$3.09B
– –
-491,116
Closed -$8.03M
SLNO
48
DELISTED
Soleno Therapeutics
SLNO
– –
-577,808
Closed -$19.3M
SUPN icon
49
Supernus Pharmaceuticals
SUPN
$2.53B
– –
-62,019
Closed -$3.21M
TERN
50
DELISTED
Terns Pharmaceuticals
TERN
– –
-409,031
Closed -$21.6M
1
2
3

Similar funds

3IP
3Chopt Investment Partners Richmond, Virginia $532M AUM 35.46% 1-Year Est. Return
ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return
IA
Icon Advisers Greenwood Village, Colorado $532M AUM 56.47% 1-Year Est. Return
KM
KP Management Edina, Minnesota $532M AUM 118.04% 1-Year Est. Return
SIA
Sovereign Investment Advisors Phoenix, Arizona $533M AUM 16.78% 1-Year Est. Return
TCMX
Technology Crossover Management XI Menlo Park, California $533M AUM 42.1% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
NAMP
NorthStar Asset Management (Pennsylvania) Blue Bell, Pennsylvania $531M AUM 27.28% 1-Year Est. Return

Catalio Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Catalio Capital Management held 51 positions worth $532M, up 11% from $479M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Catalio Capital Management withdrew a net $19.6M in Q2 2026, closing 12 positions and reducing 9 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $21.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in Avalyn Pharma worth $55.2M.

  • Catalio Capital Management's largest Q2 2026 buy was Avalyn Pharma: 1,675,830 shares worth $55.2M.
  • Catalio Capital Management added most to Gilead Sciences in Q2 2026, an estimated $13.9M increase.
  • Catalio Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $46.1M.
  • Catalio Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $21.6M.
  • Catalio Capital Management's ten largest holdings make up 57% of its $532M portfolio in Q2 2026.
  • Catalio Capital Management opened 10 new positions and closed 12 in Q2 2026.
  • Catalio Capital Management's portfolio value rose 11% quarter-over-quarter to $532M.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.